drugset / Trial / NCT06417229

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229

Phase 1 Completed 102 enrolled Celgene Corporation
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.

Timeline

Start
2024-05-28
Primary completion
2025-02-19
Completion
2025-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject CC-94676 Other / unclassified
Subject Rabeprazole Small molecule

Indications

No indication recorded.